Dr. Mark W. Grinstaff's lab at Boston University focuses on developing innovative therapeutic strategies to treat cancer and metabolic diseases. Their research is at the intersection of chemistry and biology, utilizing novel biomaterials and RNA technologies to improve drug delivery and efficacy. Key projects include addressing lung cancer through self-amplifying RNA therapies and proposing new treatments for liver disease by restoring lysosome function.

Dr. John A. Porco's lab at Boston University focuses on developing new antiviral drugs to combat mosquito-borne viruses like dengue, Zika, and chikungunya. By creating and optimizing small molecules called aglains that interact with specific host targets, the lab aims to improve treatment options for these diseases, which pose significant public health threats worldwide. The research combines medicinal chemistry with biology to better understand how these compounds work against viral infections.